Table 2.
Gender-specific treatment during hospitalization for an acute myocardial infarction (AMI)
| No. (%) of patients |
||||
|---|---|---|---|---|
| Treatment | total (n = 265) | women (n = 59) | men (n = 206) | P |
| Drug class: |
||||
| beta-blockers |
147 (55.5) |
27 (45.8) |
120 (58.3) |
0.089 |
| ACEI/ARB |
163 (61.5) |
33 (55.9) |
130 (63.1) |
0.318 |
| statins |
256 (96.6) |
56 (94.9) |
200 (97.1) |
0.417 |
| aspirin |
251 (94.7) |
52 (88.1) |
199 (96.6) |
0.010 |
| Number of drug classes: |
||||
| 4 |
107 (40.4) |
17 (28.8) |
90 (43.7) |
<0.001 |
| 3 |
81 (30.6) |
18 (30.5) |
63 (30.6) |
0.991 |
| 2 |
69 (26.0) |
22 (37.3) |
47 (22.8) |
0.026 |
| 1 |
8 (3.0) |
2 (3.4) |
6 (2.9) |
0.932 |
| Revascularization: |
||||
| PCI or CABG |
118 (44.5) |
15 (25.4) |
103 (50.0) |
<0.001 |
| any type† |
123 (46.4) |
18 (30.5) |
105 (51.0) |
<0.001 |
| PCI |
77 (29.2) |
9 (15.3) |
68 (33.2) |
<0.001 |
| CABG |
42 (15.9) |
6 (10.3) |
36 (17.6) |
<0.001 |
| thrombolysis | 10 (3.8) | 3 (5.1) | 7 (3.4) | 0.453 |
*ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; PCI – percutaneous coronary intervention; CABG – coronary artery bypass grafting.
†PCI, CABG or thrombolysis.